JT
VRDN icon

Jupiter Topco’s Viridian Therapeutics VRDN Stock Holding History

Jupiter Topco’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$505K Buy
+27,472
New +$443K ﹤0.01% 2093

Other funds holding VRDN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jupiter Topco's VRDN Position: Q2 2026 in Review

Jupiter Topco opened a new position in Viridian Therapeutics (VRDN) in Q2 2026: 27,472 shares worth $505K. The stake represents ﹤0.01% of the portfolio and ranks #2093 among its holdings.

193 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Jupiter Topco held 27,472 shares of Viridian Therapeutics worth $505K as of Q2 2026.
  • Viridian Therapeutics was a new Jupiter Topco position in Q2 2026.
  • Viridian Therapeutics made up ﹤0.01% of Jupiter Topco's portfolio in Q2 2026, its #2093 holding.
  • 193 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Jupiter Topco's 13F filing for Q2 2026, filed 14 Aug 2026.